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Sulfadoxine is predominantly used in combination with pyrimethamine, commonly known as Fansidar, for
the treatment of Plasmodium falciparum. This combination is usually less effective against Plasmodium vivax,
probably due to the innate refractoriness of parasites to the sulfadoxine component. To investigate this
mechanism of resistance by P. vivax to sulfadoxine, we cloned and sequenced the P. vivax dhps (pvdhps) gene.
The protein sequence was determined, and three-dimensional homology models of dihydropteroate synthase
(DHPS) from P. vivax as well as P. falciparum were created. The docking of sulfadoxine to the two DHPS models
allowed us to compare contact residues in the putative sulfadoxine-binding site in both species. The predicted
sulfadoxine-binding sites between the species differ by one residue, V585 in P. vivax, equivalent to A613 in
P. falciparum. V585 in P. vivax is predicted by energy minimization to cause a reduction in binding of
sulfadoxine to DHPS in P. vivax compared to P. falciparum. Sequencing dhps genes from a limited set of
geographically different P. vivax isolates revealed that V585 was present in all of the samples, suggesting
that V585 may be responsible for innate resistance of P. vivax to sulfadoxine. Additionally, amino acid
mutations were observed in some P. vivax isolates in positions known to cause resistance in P. falciparum,
suggesting that, as in P. falciparum, these mutations are responsible for acquired increases in resistance of P.
vivax to sulfadoxine.
The rapid spread of chloroquine-resistant Plasmodium fal-
ciparum malaria in many countries has led to the widespread
use of the sulfadoxine-pyrimethamine (S-P) combination, also
known as Fansidar, for the treatment of malaria. Sulfa drugs
(sulfones and sulfonamides) were first used in the 1930s for
malaria treatment. Over the next decade, numerous clinical
studies indicated that these drugs were usually effective against
P. falciparum malaria but much less so against Plasmodium
vivax malaria (13).
With the subsequent introduction of chloroquine and its
ability to rapidly control acute attacks of both P. falciparum
and P. vivax malaria, little further attention was given to the
slower-acting sulfa drugs. However, when chloroquine resis-
tance started to become a problem in the early 1960s, renewed
interest was shown in sulfa drugs and in exploiting the synergy
of these drugs in combination with dihydrofolate reductase
inhibitors. Short-acting sulfonamides soon gave way to longer-
acting sulfonamides such as sulfadoxine and sulfalene. As had
been shown earlier with the shorter-acting sulfonamides (8,
19), the addition of pyrimethamine to sulfadoxine was appre-
ciably more effective in curing chloroquine- and pyrimeth-
amine-resistant P. falciparum infections than sulfadoxine alone
(3, 14).
The antibacterial and antimalarial modes of action of these
sulfa drugs are quite similar in that they inhibit dihydro-
pteroate synthase (DHPS), an enzyme that catalyses the con-
densation of p-aminobenzoic acid with 6-hydroxymethyl dihy-
dropterin pyrophosphate to yield dihyropteroate (27). Sulfa
drugs essentially block the de novo pathway of folate synthesis,
leading to the depletion of dTTP and decreased DNA synthe-
sis in both bacteria and malaria parasites. Since the sulfon-
amides and dihydrofolate reductase inhibitors, such as py-
rimethamine, act at different points of the parasite’s metabolic
pathway, marked potentiation of antimalarial activity is usually
observed with these drug combinations. The synergistic S-P
combination is now used widely as a first-line drug in areas
where P. falciparum has become resistant to chloroquine and
pyrimethamine.
However, in most malarious countries located outside the
African continent, P. vivax coexists with P. falciparum. Limited
diagnostic facilities in many of these countries preclude a spe-
cies diagnosis of malaria made upon microscopic examination
of blood films. Since the two species cannot be differentiated
on clinical grounds, malaria infections, whether due to P. fal-
ciparum or P. vivax, are treated with S-P. Unfortunately, S-P is
less effective in clearing fever and parasites in patients infected
with P. vivax than in those infected with P. falciparum (9, 11).
Earlier studies had already shown that sulfa drugs are less
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active against P. vivax than against P. falciparum (16, 18, 20).
Since there is already widespread resistance of P. vivax to
pyrimethamine, the refractoriness of parasites to the sulfa
drugs probably deprives the S-P combination of much of its
synergistic activity when given to patients infected with P. vivax
malaria.
The basis for the lack of response or innate resistance of P.
vivax to sulfa drugs is not clear. However, it is highly probable
that the mechanism involved in resistance of P. vivax to sulfa-
doxine is similar to that in P. falciparum. Sulfadoxine resistance
in P. falciparum has been demonstrated to result from genetic
mutations in the parasites’ dhps gene (23, 26, 28). Several
mutations in this gene resulted in increased 50% inhibitory
concentration (IC50) levels of P. falciparum to sulfadoxine.
Among these, the A437G mutation has been shown by trans-
fection experiments to be the initial mutation, causing a five-
fold increase in IC50. Higher IC50 levels were associated with
the additional mutations S436F/A, K540E, A581G, and A613S
(26). Therefore, sequencing the P. vivax dhps gene and devel-
oping an understanding of this resistance mechanism may
help in formulating a better antifolate-sulfonamide com-
bination that is effective against both P. falciparum and
P. vivax.
In this paper, we report the cloning and sequencing of the
P. vivax pppk-dhps (pvpppk-dhps) gene and compare it to the
P. falciparum homologue. Model three-dimensional structures
of DHPS from P. falciparum and P. vivax derived from homol-
ogy to other DHPS proteins were constructed, and the active
sites were identified. Sulfadoxine was then docked into these
sites based on crystal structures of other DHPS proteins bound
to similar sulfa drugs. The putative sulfadoxine-binding sites
correlated with sequence polymorphisms associated with P.
falciparum and P. vivax resistance. An explanation for the dif-
ference in binding of P. falciparum and P. vivax to sulfadoxine
is presented, and the future role for sulfa drugs in combating
malaria is discussed.
MATERIALS AND METHODS
Parasites. Several blood samples containing P. vivax were obtained from
Australian travelers returning from Papua New Guinea (PNG) and East Timor
and were frozen at70°C. The patient blood was thawed, and genomic DNA was
isolated by a method described elsewhere (7). Total RNA was isolated with the
QIAGEN RNeasy kit. P. vivax samples from Maesod, Thailand (21), Fujian
Province, China (1993), Morong, Philippines (1992), and West Papua (1999) (22)
were kindly provided by B. Russell (AFRIMS, Bangkok, Thailand), Gao Qi
(Jiangsu Institute of Parasitic Diseases, Wuxi, China), Cielo Pasay (Research
Institute for Tropical Medicine, Manila, Philippines), and E. Tjitra (National
Institute of Health Research and Development, Jakarta, Indonesia), respec-
tively.
Cloning and sequencing the P. vivax pppk-dhps gene. (i) Amplification and
sequencing of a genetic fragment conserved between species. The pppk-dhps
genes of P. falciparum, Escherichia coli, Toxoplasma gondii, Neisseria meningitidis
(GenBank accession numbers Z30654, X68777, U81497, and X68066, respec-
tively), and Pneumocystis carinii (EMBL accession number U66282) were
aligned, and the species conserved regions were identified. A pair of degenerate
primers (DHPS1 and DHPS2), as shown in Fig. 1, were made to amplify a 114-bp
fragment of the gene from a PNG isolate of P. vivax genomic DNA (Table 1).
PCR was performed with 75 ng of each primer, 200 M deoxynucleoside triphos-
phates, 2 mM MgCl2, 1 l of genomic DNA, and 2.5 U of AmpliTaq Gold.
Genomic DNA from P. falciparum and an uninfected human were used as
positive and negative controls, respectively. The PCR was initiated by one cycle
FIG. 1. Cloning strategy for the pvpppk-dhps gene. The expressed pppk-dhps sequence (exons) is represented by shaded boxes, and introns are
represented by nonshaded boxes. A dotted vertical line indicates where the two coding regions join. Solid horizontal lines represent fragments of
DNA or RNA sequenced to obtain the entire pppk-dhps gene sequence. A dip in the solid line flanked by two vertical lines represents a gap in
the sequence. The dotted horizontal line indicates that the fragment is longer than shown. The numbering indicates distances in base pairs from
the start codon. Numbers in brackets represent the sizes (in base pairs) of DNA or RNA fragments. Arrows indicate positions and orientations
of primers.
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at 94°C for 10 min followed by 45 cycles of 93°C for 50 s, 42°C for 50 s, and 72°C
for 50 s. Sequencing this 114-bp fragment allowed the design of the pvdhps-
specific primers PvDHPS3 and PvDHPS4.
(ii) Screening P. vivax cDNA and YAC libraries and sequencing inserts of
positive clones. Four P. vivax cDNA libraries (K. Fischer, unpublished data) were
constructed from patient-derived material (Belem, Brazil). PCR screening of
cDNA libraries was achieved by using the vector specific primers T3 and T7 in
combination with the pvdhps-specific primers PvDHPS4 and PvDHPS3, respec-
tively (Fig. 1). The PCR products were sequenced directly. The P. vivax yeast
artificial chromosome (YAC) library was constructed from P. vivax-infected
erythrocytes from patients whom presented themselves to the Tropical Medical
Centre in Rondonia, Porto Velho-Brazil, Brazil (5, 6). The YAC library was
transferred to high-density nylon filters and screened by hybridization (6) with a
pvdhps fragment obtained from a cDNA clone. A YAC clone containing the
pvdhps gene was identified, prepared in agarose blocks, and separated by pulsed-
field gel electrophoresis (5, 6). The agarose band containing the YAC DNA was
isolated and digested with endonuclease as described by de Bruin et al. (10). The
fragment containing the 3 end of pvdhps from the YAC insert was amplified by
inverse PCR (25). Sequence tag sites were cloned into the pCR2.1 vector (In-
vitrogen) and sequenced.
(iii) Amplification of the entire pvpppk-dhps gene from isolated parasite DNA
and RNA. Based on the DNA sequence obtained from the overlapping gene
segments from the P. vivax YAC and cDNA libraries, several primers were
designed to amplify the entire gene. Nested PCR was performed to amplify
the full-length gene from genomic DNA with primers 9 and 8 as shown in Fig. 1
(10 min at 94°C, 50 s at 94°C, 50 s at 50°C, and 3 min at 72°C for 40 cycles) for
first-round PCR and primers A and B (10 min at 94°C, 50 s at 94°C, 50 s
at 50°C, and 3 min at 72°C for 40 cycles) for second-round PCR. The
full-length coding region of the gene was obtained from total RNA by re-
verse transcription-PCR. This was carried out with the One-Step reverse
transcription-PCR kit (Invitrogen) supplemented with Pfu by using primers 9
and 8 (Table 1) (30 min at 42°C, 2 min at 94°C, 50 s at 94°C, 50 s at 50°C, and
3 min at 72°C for 40 cycles) for first-round PCR, followed by second-round
PCR with the Long PCR kit (Invitrogen) containing Pfx with primers A and
B (2 min at 94°C, then 15 s at 94°C, 30 s at 55°C, and 3 min at 68°C for 35
cycles) (Table 1). PCR products amplified from both genomic DNA and total
RNA were purified by using the QIAquick PCR purification kit (Qiagen) and
then sequenced to identify introns and, hence, determine the full-length
coding region.
Amplification and sequencing of the dhps portion from P. vivax isolates. The
dhps portion of the gene from several P. vivax isolates was amplified by nested
PCR. The first-round PCR was identical to that used to amplify the full-length
gene, and the second-round PCR was performed with primers D and B to
amplify only pvdhps (10 min at 94°C, 50 s at 94°C, 50 s at 50°C, and 1.5 min at
72°C for 40 cycles) (Table 1). The PCR product was purified and sequenced as
described above.
Molecular modeling. (i) Homology models of P. falciparum and P. vivax DHPS.
Homology models of DHPS from P. falciparum and P. vivax were constructed by
using the homology package of InsightII from Molecular Simulations, Inc. The
models were based on the DHPS crystal structures of E. coli (1AJ0) (1), Ther-
moplasma acidophilum (1PMA) (17), and Mycobacterium tuberculosis (1EYE)
(2). The crystal structure template sequence segments of highest sequence iden-
tity and best secondary structure correlation were assigned to the DHPS se-
quences. Where the templates did not match the models, suitable loops with
appropriate conformations were assigned from protein structures found in the
Brookhaven PDB database. The models were minimized by using Discover
(Molecular Simulations, Inc.) to a root mean square deviation of less than 106
kcal/mol/Å by using steepest descents and conjugate gradients, taking into ac-
count morse and cross terms and charges. The DHPS models were validated by
using Procheck.
(ii) Docking of sulfadoxine and other sulfa compounds to the DHPS models.
Docking of the sulfa drugs to both P. falciparum and P. vivax DHPS models was
performed by using genetic optimization of ligand binding from the Cambridge
Crystallographic Data Centre.
(iii) Predicted sulfadoxine-binding site. Contact residues were defined as
those that were found to be within 3 A˚ of the relevant sulfa compounds com-
plexed to the corresponding Plasmodium DHPS models.
Nucleotide sequence accession number. DNA sequences reported in this
paper have been deposited in GenBank under the accession number
AY186730.
RESULTS
The P. vivax pppk-dhps gene. A region of genomic DNA
covering 3,031 bp of the entire pvpppk-dhps gene was se-
quenced. Putative start and stop codons from within the
pvpppk-dhps gene were determined by comparison with the
P. falciparum pppk-dhps gene. The entire gene contains
2,591 bp (Fig. 1) and two introns that were identified by
comparing sequences of genomic DNA and total RNA. In-
tron 1 is 246 bp in length (nucleotides 128 to 373) and in-
tron 2 is 149 bp in length (nucleotides 2327 to 2475). The cod-
ing region of the gene contains 2,196 bp encoding 731 amino
acids.
Sequence homology between the P. vivax pppk-dhps gene and
other Plasmodium pppk-dhps genes. The DNA and putative
amino acid sequences from the pvpppk-dhps gene were aligned
and compared to sequences of other Plasmodium species lo-
cated in the GenBank database. It was found that, at the amino
acid level, P. vivax PPPK-DHPS has 56, 56, 59, and 50% ho-
mology to PPPK-DHPS from P. berghei, P. chabaudi, P. falci-
parum, and P. yoelii, respectively (Table 2). The pppk-dhps
sequences are highly homologous between different species of
malaria parasites; however, a repetitive domain that was not
found in the other malaria parasites sequences exists at the
pvpppk-dhps C-terminal region. This domain is composed of
7-amino-acid tandem repeats.
Mutations in the P. vivax dhps gene. The dhps portion of the
pvpppk-dhps gene was amplified and sequenced from 14 iso-
lates with geographically diverse backgrounds (Table 3). A
sequence comparison revealed only two amino acid changes
among the P. vivax isolates: A383G in 4 isolates from Thailand
and 2 isolates from West Papua and A553G in 4 Thai isolates,
equivalent to A347G and A581G in P. falciparum DHPS, re-
spectively. Amino acids in P. vivax DHPS at positions corre-
sponding to those in P. falciparum DHPS where mutations
were reported are shown in Table 3. The amino acid at position
585 in all of the P. vivax DHPS sequences contained a Val
TABLE 1. Primers used to amplify the entirety and fragments of
the P. vivax pppk-dhps gene
Primer Sequence (5–3)
PvDHPS-1 ...........................CCTGAYTCYTTYTCVGAYG
PvDHPS-2 ...........................GGATTCGCCRCCDAYRTC
PvDHPS-3 ...........................GCGGTTTATTTGTCGATCC
PvDHPS-4 ...........................GTCAATCACGCTCGCC
PvDHPS-A..........................CCATGGAGGATTCAAACAC
PvDHPS-B ..........................GAGATTACCCTAAGGTTGATGTATC
PvDHPS-C ..........................ATCATAAGCATCGACACGGTC
PvDHPS-D..........................GGTTTATTTGTCGATCCTGTG
PvDHPS-8 ...........................TTGAAACACGCATTATGGTATCG
PvDHPS-9 ...........................AAGCGTAGCGACAGAAGAACG
TABLE 2. Comparison of amino acid sequences of Plasmodium
PPPK-DHPS
Organism
% Homology to:
P. chabaudi P. falciparum P. vivax P. yoelii
P. berghei 88 58 56 82
P. chabaudi 60 56 78
P. falciparum 59 54
P. vivax 50
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compared with an Ala in wild-type P. falciparum DHPS se-
quences.
P. vivax and P. falciparum DHPS homology models. Homol-
ogy models of P. vivax and P. falciparum DHPS were con-
structed based on the deduced crystal structures of DHPS from
E. coli (1AJ0), T. acidophilum (1PMA), and M. tuberculosis
(1EYE). The amino acid sequence alignment and structurally
conserved region (SCR) elements of DHPS from E. coli DHPS
(1AJ0) and the two models are shown in Fig. 2. The SCRs
predicted in both the P. falciparum and P. vivax DHPS models
were comparable to those reported in the three template struc-
tures, with the exception of one omission of a large stretch of
amino acids in P. falciparum (positions 620 to 656) and the
omission of two large stretches of amino acids in P. vivax
(positions 411 to 438 and 592 to 681). These amino acids
could not have a structural orientation assigned to them due
to the lack of homology with the crystal structure templates.
However, these omissions are unlikely to affect the active
sites or the predictions made from the resultant homology
models.
The predicted sulfadoxine-binding site in P. vivax DHPS
differs from the equivalent site in P. falciparum by one amino
acid. Sulfadoxine was docked into the predicted active site in
the P. falciparum DHPS model as well as the equivalent active
site in the P. vivax DHPS model. The docking was guided by
the orientation of the sulfa drug sulfanilamide in complex with
DHPS from E. coli (1AJ0). Multiple energy minimizations
were performed, yielding an energy minima and a location
most representative of the binding site (Fig. 3A). A total of 10
contact residues were predicted to directly interact with sulfa-
doxine (Table 4). The P. falciparum predicted sulfadoxine-
FIG. 2. Amino acid sequence alignment of DHPS from P. vivax (Pvi), P. falciparum (Pfa), and E. coli (Eco). SCR elements are represented by
grey shading. Residues putatively involved in sulfadoxine binding are shown in bold, and residues known to be associated with mutations that lead
to sulfadoxine resistance in P. falciparum are boxed. The residue V585 from DHPS in P. vivax, predicted to be responsible for innate resistance
to sulfadoxine, is circled.
TABLE 3. Amino acid changes observed in P. vivax DHPS genes in
several isolates
Allelic
type Origin (no. of isolates)
Amino acid at positionsa:
436,
382
437,
383
540,
512
581,
553
613,
585
Wild East Timor (1), Brazil (1),
West Papua (1), China
(2), Philippines (1),
PNG (1)
S A K A V
Mutant West Papua (2),
Philippines (1)
S G K A V
Mutant Thailand (4) S G K G V
a The first position listed is for P. falciparum, and the second position listed is
for P. vivax.
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binding site contained an A613 residue, whereas the P. vivax
sulfadoxine-binding site contained a V585 residue at the equiv-
alent position. This was the only difference between the pre-
dicted sites of both models for sulfadoxine binding (Fig. 3A
and Table 4).
Mutations in DHPS from P. falciparum associated with re-
sistance to sulfadoxine are located in or near the P. falcipa-
rum DHPS sulfadoxine-binding site. The mutations S436F/
S436A, A437G, K540E, A581G, and A613S shown in Fig. 3B
that are known to cause resistance by P. falciparum to sulfa-
doxine were separately introduced into the P. falciparum
DHPS model. The model was energy minimized for each mu-
tant, and from these results, predictions were made. The re-
placement of Ser with Phe at position 436 is a major alter-
ation not allowing sulfadoxine to bind due to the bulky ring
causing a massive steric hindrance. A putative hydrogen bond
from S436 to sulfadoxine or S436 to a putative sulfate ion
would also be destroyed, destabilizing that region of the bind-
ing site. Replacing the same Ser with an Ala would have a
much less serious effect with little steric hindrance at all. An
Ala-to-Gly change at position 437 would result in a loss of
hydrophobic interaction between the Ala side chain and sulfa-
doxine ring, significantly reducing the binding affinity (Fig.
4A). K540 is a surface residue located approximately 10 A˚
away from the sulfadoxine-binding site. A K540E change at
this position results in a positive-to-negative charge reversal.
This in turn reorients R610 and, hence, the contact residues
P438 and K609, causing a moderate change to the binding
site (Fig. 3B). Similarly, A581 is approximately 9 A˚ from the
sulfadoxine-binding site. However, it resides in a turn that
gains increased flexibility when A581 is replaced with Gly,
causing disturbance to the contact residue F580 but only a
very minor disturbance to the binding site (Fig. 3B). The Ala-
to-Ser mutation at position 613, although subtle, would also
result in a reduction in hydrophobic contacts between itself
and sulfadoxine coupled with the introduction of some polarity
through the lone pairs on the serine side chain oxygen (Fig.
3B).
V585 in P. vivax DHPS is predicted to disrupt the sulfadox-
ine-binding site. Energy minimization of the P. falciparum
DHPS sulfadoxine and P. vivax DHPS sulfadoxine complexes
revealed an increase in energy in the P. vivax DHPS sulfadox-
ine complex caused by steric hindrance from the larger V585
residue compared with the smaller A613 residue in the P.
FIG. 3. (A) Stick representation overlay of the putative sulfadox-
ine-binding sites from P. falciparum and P. vivax DHPS. Sulfadoxine is
shown in green stick form with its electron densities as small dots. All
amino acids shown in thick (contact residue associated with resistance)
or thin stick form are predicted contact residues with the exception of
K540/K512 and A581/A553. S436/S382 (red), A437/A383 (red), A613/
V585 (blue), K540/K512 (orange), and A581/A553 (orange) are all
associated with P. falciparum resistance to sulfadoxine. Innate resis-
tance to sulfadoxine in P. vivax is predicted to be a consequence of the
V585 residue. (B) Stick representation of the putative binding site in
DHPS from P. falciparum for sulfadoxine. The mutations S436F,
A437G, and A613S associated with resistance by P. falciparum to
sulfadoxine have been shown to demonstrate their potential effects on
the binding site.
TABLE 4. Predicted sulfadoxine contact residues in P. falciparum
and P. vivax DHPS
Amino acid position
no. in P. falciparum
Amino acid in: Amino acid position
no. in P. vivaxP. falciparum P. vivax
436 S S 382
437 A A 383
438 P P 384
580 F F 552
608 R R 580
609 K K 581
613 A V 585
663 Y Y 688
666 N N 691
688 H H 713
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falciparum DHPS sulfadoxine complex (Fig. 3A). The larger
side chain of the valine caused a steric hindrance in this region
of the binding site compared with alanine, resulting in the
separation of the two predicted hydrogen bonds from S382 and
R580 to sulfadoxine (Fig. 4B).
Effect of mutations in the P. vivax DHPS protein on sulfa-
doxine binding. Two mutations were identified from sequenc-
ing the dhps portion of the pvpppk-dhps genes from 14 P. vivax
isolates with diverse geographical backgrounds: A383G and
A553G, equivalent to A437G and A581G, respectively, in P.
falciparum (Table 3). The modeling predicts that the disrup-
tion that these two mutations cause in P. vivax to the sulfadox-
ine-binding site is similar to that of P. falciparum (Fig. 4A and
B).
Binding interactions of other sulfa drugs to the P. falcipa-
rum and P. vivax sulfadoxine-binding site. Sulfadimethoxine,
sulfamethoxypyridazine, sulfadiazine, sulfalene, sulfathia-
zole, sulfamethoxazole, sulfafurazol, dapsone, and acedap-
sone were energy minimized into the P. falciparum and P.
vivax sulfa drug binding sites to determine from a molecular
level whether these drugs may be used as components of
future drug regimens. It was predicted that V585 would
interfere with the binding of sulfadoxine, sulfadimethoxine,
sulfamethoxypyridazine, and sulfalene to DHPS from P.
vivax (data not shown). In contrast, it was predicted that the
binding of sulfadiazine, sulfathiazole, sulfamethoxazole, sul-
fafurazole, dapsone (Fig. 5), and acedapsone to DHPS from
P. vivax would not be affected by the presence of V585. The
model was also used to investigate the effect that the A383G
mutation in P. vivax DHPS isolates would have in the bind-
ing of other sulfa drugs. Unfortunately, it was predicted that
this change would significantly reduce the binding of all of
the aforementioned sulfa drugs to DHPS from P. vivax,
FIG. 4. (A) Effect of the A437G mutation in DHPS from P. falci-
parum. The equivalent residues from Fig. 3A are shown here for P.
falciparum with the exception of residue A613 (dark blue). There is a
loss of hydrophobic interactions between the A437G residue and sul-
fadoxine (colored as described for Fig. 3A). There is a reduction in
binding of sulfadoxine to DHPS from P. falciparum when the A437G
mutation is present. (B) Illustration of the effect of V585 at the DHPS
P. vivax binding site compared with A613 in P. falciparum DHPS.
P. ivax residues prior to energy minimization are displayed in stick form
and colored red and blue. Sulfadoxine is also shown in green stick form
in the equivalent position it adopted in the P. falciparum binding site
and in black at the position adopted after energy minimization,
allowing for the effect of V585. Hydrogen bond donor and acceptor
atoms are colored light blue and are broken after energy minimi-
zation. The V585 interferes with binding of sulfadoxine to DHPS
from P. vivax.
FIG. 5. Stick representation of the putative binding site in DHPS
from P. vivax for dapsone. Dapsone is shown in fluorescent green
stick form with its electron densities as small dots. Residues are
colored and rendered as described for Fig. 3, with the exception of
position V585. The equivalent residue A613 in DHPS from P. falci-
parum and residue V585 have been overlaid to show that dapsone
does not interact directly with either residue. Dapsone binding to
DHPS from P. vivax is not predicted to be hindered by the presence
of V585.
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given that both classes contain very similar core elements
within their structures and that this mutation occurs at such
a region.
DISCUSSION
Unlike most antimalarial drugs, sulfadoxine is innately less
effective against asexual erythrocytic parasites of P. vivax than
P. falciparum. In Technical Report Series 711, the World
Health Organization recommended that antifolate-sulfon-
amide combinations should not be used for the therapy of P.
vivax infections because of widespread resistance to antifolates
and the inadequate efficacy of sulfonamides against this para-
site (29). To determine the molecular mechanism causing the
inadequate efficacy of sulfonamides against P. vivax, we have
cloned and sequenced the pppk-dhps gene in P. vivax and
investigated the putative sulfadoxine-binding sites in DHPS
from P. falciparum and P. vivax.
The dhps gene of P. vivax, as in P. falciparum, is connected
to the pppk gene, which codes for a bifunctional enzyme. The
protein sequence of P. vivax DHPS is moderately homologous
to those of other malaria species; however, sections of the
protein are more homologous to other malaria species and to
E. coli. This made it possible for homology models of P. falci-
parum and P. vivax DHPS to be constructed based on the E.
coli DHPS crystal structure. The models allowed a putative
binding site for sulfadoxine in both P. vivax and P. falciparum
to be identified based on the crystal structures of E. coli DHPS
complexed to sulfanilamide and the use of energy minimiza-
tion.
The P. falciparum DHPS model was first utilized to help
understand the effects that known mutations in DHPS from P.
falciparum have on sulfadoxine binding. Predictions from en-
ergy minimizations were compared with transfection results
published by Triglia et al. (26), where various P. falciparum
DHPS mutant alleles were transfected to replace the wild-type
P. falciparum dhps gene and sulfa drug IC50s of the mutant
combinations determined. The mutations S436F, S436A,
A437G, and A613S associated with sulfadoxine resistance in
P. falciparum were all found to be located within 3 A˚ of the P.
falciparum DHPS sulfadoxine-binding site. These mutant com-
plexes, when energy minimized, resulted in higher energies
and, hence, lower binding capacities to sulfadoxine, consistent
with significant increases in IC50s obtained in the transfection
experiment (26).
The two other mutations studied, A581G and K540E, are
not predicted to be in direct contact with sulfadoxine in the
P. falciparum DHPS sulfadoxine-binding site. The mutation
A581G only resulted in a slight increase in energy when in-
troduced into the complex. It resides approximately 9 A˚ from
the binding site, causing minor secondary effects through
other contact residues. The prediction is consistent with a
slight increase in its IC50 in the transfection experiment
(26). The K540E mutation is also approximately 10 A˚ from
the binding site but results in a side chain charge reversal
from positive to negative. This mutation alone resulted in a
larger increase in energy that is consistent with the addi-
tional increase in IC50 when this mutation was compared in
combination with and without other mutations in the trans-
fection experiment (26). It should be noted here that the
K540E mutation is not predicted to cause treatment failure
when found independent of other mutations. The K540E
mutation is primarily found in combination with up to 5 addi-
tional mutations in DHPS and dihydrofolate reductase (4, 12,
15, 24). It is most likely that K540E correlates well with treat-
ment failure due to its combination with other mutations in
these genes.
The P. vivax homology model of DHPS was then used to
analyze the effect of V585 in comparison to A613 in DHPS
from P. falciparum. Energy minimization of sulfadoxine
bound independently to DHPS from both P. vivax and P.
falciparum resulted in a higher energy for the P. vivax complex
due to the added bulk of the valine side chain interfering with
sulfadoxine. This result is supported experimentally by the
existence of an A613S mutation in P. falciparum (equivalent to
position 585 in P. vivax) that has been shown to be associated
with sulfadoxine resistance (26). This, coupled with the re-
sult that all the other putative binding residues were iden-
tical between the two species, suggests that it is highly prob-
able that V585 is largely responsible for P. vivax resistance
to sulfadoxine.
V585 is the only amino acid that is different between the P.
falciparum and P. vivax predicted sulfadoxine-binding sites and
is present in the 14 geographically diverse P. vivax isolates
sequenced so far. We therefore hypothesize that the existence
of V585 is possibly a wild-type residue, thus providing a logical
explanation for the observed innate resistance of P. vivax to
sulfadoxine. It is an early speculation that requires more DHPS
sequencing data from P. vivax isolates from various geograph-
ical settings, especially from areas with limited S-P usage, to
confirm this hypothesis.
In contrast to the apparent sequence conservation of the
V585 residue, an A383G mutation was detected in some iso-
lates of P. vivax. It was predicted, by use of energy minimi-
zation, that the A383G mutation would cause a reduction in
binding of sulfadoxine to P. vivax DHPS. This same change
has also been found to be essential for conferring sulfadox-
ine resistance in P. falciparum. Since it is only found in some
P. vivax isolates, it may represent the acquired resistance
that developed as a result of a relatively recent selection
event due to the widespread intensive use of sulfadoxine and
other sulfa drugs. In the limited number of sequencing ex-
periments that we performed, this mutation is most preva-
lent in isolates from Thailand, which is consistent with high
resistance levels observed for P. falciparum in the area,
suggesting a high selection pressure on both species of Plas-
modium.
The construction of these DHPS models also made it pos-
sible to test whether other sulfa drugs could be predicted to be
more useful than sulfadoxine against P. vivax. In particular, the
testing of dapsone has significant implications due to the re-
cent development of a new sulfa drug-dihydrofolate reductase
inhibitor combination comprised of dapsone and chloro-
proguanil, which will soon replace S-P. Interestingly, dapsone
is much smaller then sulfadoxine and is not predicted to bind
directly to V585. Energy minimization of the P. vivax DHPS
dapsone complex with V585 yielded no significant energy dif-
ference compared to the same complex energy minimized with
A585, the equivalent amino acid observed in P. falciparum
DHPS. Unfortunately though, unlike V585, the A383G muta-
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tion is predicted to affect all sulfa drugs that can potentially
bind to P. vivax consistent with the cross-resistance profile for
three sulfonamides and a sulfone demonstrated by Triglia et al.
(24). These predictions may provide an explanation for the
variable effect of dapsone in the treatment of P. vivax pa-
tients (18, 20). That is, dapsone may be effective in treating a
patient infected with a V585 P. vivax isolate but most probably
fails when a patient is infected with a V585/A383G P. vivax
isolate.
Due to the difficulties involved in culturing the P. vivax
parasite, the in vivo effect of having V585, A383G, and A553G
in P. vivax is difficult to demonstrate. The identification and
imilarities of the sulfadoxine-binding sites in DHPS from
both P. falciparum and P. vivax suggest that A383G and
A553G in P. vivax DHPS will result in similar increases in
resistance to sulfadoxine in P. falciparum. It may be inferred
that this is the case, given that Russell et al. (21) have shown
that four of the Thai isolates (V585/A383G/A553G) present-
ed in this paper are resistant to sulfadoxine (MICs, 500,000
ng/ml).
The identification of V585 in DHPS from P. vivax as well as
homology modeling of DHPS itself has made it possible to
predict that the V585 residue is most probably responsible for
resistance to sulfadoxine by P. vivax and is potentially the
underlying cause of innate resistance. It is also predicted by
modeling that this residue would not affect the sensitivity of
P. vivax to dapsone and several other potential sulfa drugs.
Unfortunately though, the wide use of sulfa drugs in the treat-
ment of bacterial and plasmodium infections may have con-
tributed to the selection of P. vivax populations with the mu-
tations A383G and/or A553G. The presence of mutations
affecting the sulfa drug binding site common to most sulfa
drugs may render dapsone, and other sulfa drugs not pre-
dicted to be affected by V585, useless for the treatment of P.
vivax. This situation and the spread of chloroquine resis-
tance in P. vivax emphasizes the urgent need to develop
alternative drugs and drug strategies for effectively treating
both P. falciparum and P. vivax.
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